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a heightened anti-inflammatory
response. This multi-step screening
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clinical outcomes of cell-based therapies.
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Poor homing of systemically infused cells to disease
sites may limit the success of exogenous cell-based
therapy. In this study, we screened 9,000 signal-
transductionmodulators to identify hits that increase
mesenchymal stromal cell (MSC) surface expression
of homing ligands that bind to intercellular adhesion
molecule 1 (ICAM-1), such as CD11a. Pretreatment
of MSCs with Ro-31-8425, an identified hit from this
screen, increased MSC firm adhesion to an ICAM-
1-coated substrate in vitro and enabled targeted
delivery of systemically administered MSCs to in-
flamed sites in vivo in a CD11a- (and other ICAM-1-
binding domains)-dependent manner. This resulted
in a heightened anti-inflammatory response. This
represents a new strategy for engineering cell hom-
ing to enhance therapeutic efficacy and validates
CD11a and ICAM-1 as potential targets. Altogether,
this multi-step screening process may significantly
improve clinical outcomes of cell-based therapies.INTRODUCTION
While exogenous cell therapy is a promising approach for treat-
ing several tragic diseases (de Girolamo et al., 2013), a major
challenge is that the majority of cell types exhibit poor homing
to disease sites (Karp and Leng Teo, 2009). Herein, we report
for the first time a multi-step process that includes a medium-
throughput screen to detect small molecules that improve
targeting of systemically infused mesenchymal stromal cellsCe(MSCs) to sites of inflammation. MSCs are promising candidates
for cell therapy given their pleotropic properties (Hoogduijn et al.,
2010; Prockop and Oh, 2012). Specifically, MSCs can be readily
isolated from bone marrow, fat, and other adult tissues, thus
avoiding ethical issues, and can be expanded under ex vivo con-
ditions to obtain a sufficient quantity for transplantation (Domi-
nici et al., 2006). They are considered immune evasive (Ankrum
et al., 2014), and their multi-lineage differentiation potential as
well as potent immunomodulatory properties prompted their
exploration in over 420 clinical trials as potential treatment
for many tragic diseases (https://clinicaltrials.gov, December
2014). While results from preclinical animal studies have been
encouraging and hundreds of millions of allogeneic MSCs can
be safely administered systemically to patients, clinical trials
have produced mixed results and the translational potential of
MSCs has not yet been realized (Ankrum and Karp, 2010; Fran-
c¸ois and Galipeau, 2012). The majority of clinical trials involve
systemic infusion of MSCs, yet MSCs exhibit poor homing to
diseased or damaged tissues (Ankrum and Karp, 2010). Key li-
gands of the classical cell-homing cascade that mediate dy-
namic cell interactions with activated endothelium are minimally
expressed by MSCs or lost during in vitro expansion (Rombouts
and Ploemacher, 2003; Sarkar et al., 2011). Modifying MSCs
with homing ligands via DNA transfection and different surface
modifications improves their targeting to diseased sites (Enoki
et al., 2010; Sackstein et al., 2008; Sarkar et al., 2011). However,
such approaches could be challenging to scale up in a cost-
effective manner and include safety concerns in the case of viral
modifications. Manipulation of signaling pathways via small-
molecule pretreatment is a simple, cost-effective, and scalable
approach to improve control over cell fate. Furthermore, as
small-molecule pretreatment only transiently activates signal
transduction pathways, and because the small molecule isll Reports 10, 1261–1268, March 3, 2015 ª2015 The Authors 1261
not directly delivered to patients, safety is another advantage.
Although several high-throughput screens of bioactive com-
pounds have been performed to identify molecules that modu-
late cellular processes relevant to cell therapy, few have been
translated into promising in vivo preclinical results (Cutler et al.,
2013). For instance, a zebrafish high-throughput screen yielded
a stabilized prostaglandin that improves hematopoietic stem cell
homeostasis and is currently being examined in a phase 2 clin-
ical trial (Cutler et al., 2013). In this study, we describe a
screening platform to identify small molecules that augment
MSC therapeutic potential via increased adhesion to intercellular
adhesion molecule 1 (ICAM-1). Ro-31-8425, identified in this
screen to upregulate CD11a expression, enhanced MSC firm
adhesion to ICAM-1, promoted targeting of systemically infused
MSCs to sites of inflammation, and boosted their therapeutic
impact.
RESULTS
A Medium-Throughput Screen of 9,000 Compounds
Identified Ro-31-8425, a Kinase Inhibitor that
Upregulates CD11a Expression on the MSC Surface
In this study, we aimed to increase MSC surface expression of
key homing ligands via small-molecule pretreatment to improve
homing of systemically administered MSCs to sites of inflamma-
tion (Graphical Abstract). Integrins, such as vascular cell adhe-
sion molecule 1, were previously implicated in MSC homing
(Teo et al., 2012), and engineering MSCs (via antibody [Ab]
coating or viral DNA transfection) to overexpress integrins can
promote targeting of systemically infused MSCs to disease sites
(Ko et al., 2010; Kumar and Ponnazhagan, 2007). We focused on
surface expression of ligands that bind ICAM-1, such as CD11a,
otherwise known as integrin alpha L (ITGAL). CD11a combines
with integrin beta 2 (CD18) to create lymphocyte function-asso-
ciated antigen-1 (LFA-1), which serves a central role in mediating
leukocyte firm adhesion, an important step in the inflammatory
leukocyte-homing cascade (Luster et al., 2005).
For detection of CD11a on cell surface, we used a PE-CY5-
conjugated anti-CD11a Ab. As shown in Figure 1A, CD11a is
highly expressed on promyelocytic leukemia cells (HL-60, pos-
itive control), but not on the surface of culture-expanded MSCs.
This anti-CD11a Ab was then used in a medium-throughput
screening of 9,000 compounds, including a proprietary collec-
tion of 2,500 signaling pathway modulators, to identify candi-
date molecules that increase expression of CD11a on the
MSC surface. Cells were pretreated with each small molecule
(24 hr), followed by incubation with a PE-CY5-conjugated
anti-CD11a Ab to detect its expression on the MSC surface
(Figure 1B; Experimental Procedures). Our screen identified
six compounds that significantly increased the expression of
CD11a on the MSC surface. The most potent molecule
emerging from this screen was the kinase inhibitor Ro-31-
8425 (CAS #131848-97-0) (Figure S1A), previously shown to
have an inhibitory effect on PKC (Muid et al., 1991). As shown
Figure 1C, Ro-31-8425 induced a dose-dependent increase
in the percentage of CD11a-positive MSCs as quantified
by mass cytometry (CyTOF; see Experimental Procedures).
Evaluation of MSC viability demonstrated that Ro-31-8425 did1262 Cell Reports 10, 1261–1268, March 3, 2015 ª2015 The Authorsnot significantly compromise cell viability at concentrations of
0.25–4 mM following a 24 hr pretreatment (Figure S1B; Ro-31-
8425 exhibited toxicity only at >4 mM post-72 hr pretreatment
of MSCs) and did not upregulate mRNA levels of CD18 (integrin
b2, known to pair with CD11a to form LFA-1; Figure S1C). Of
note, Ro-31-8425 did not substantially alter the MSC secretome
(Figure S1D; out of 48 secreted factors tested via Ab-based
multiplex assays, only 3 showed statistically significant changes
in response to Ro-31-8425 pretreatment). As shown in Fig-
ure 1C, CyTOF analysis demonstrated that Ro-31-8425 treat-
ment at 3 mM triggered a significant increase in the percentage
of MSCs exhibiting surface expression of CD11a compared to
virtually no CD11a+ MSCs under control conditions. The per-
centage of CD11a+ MSCs in response to Ro-31-8425 (3 mM
for 24 hr) was stable for at least 4 days (Figure S2A; similar pre-
treatment conditions were used for all subsequent experi-
ments). As shown in Figure 1D, RT-PCR analysis revealed that
Ro-31-8425 also significantly increased CD11a mRNA levels
in MSCs, with peak levels observed 14 hr post-incubation, indi-
cating an impact of Ro-31-8425 pretreatment on MSC CD11a
also at the transcriptional level. Importantly, Ro-31-8425
increased CD11a expression to a similar magnitude on MSCs
from multiple donors (Figure S2B). Establishing a donor-inde-
pendent response is critical for successful clinical translation
of exogenous cell therapy.
Pretreatment of MSCs with Ro-31-8425 Enhanced MSC
Firm Adhesion to an ICAM-1-Coated Surface under
Dynamic Flow Conditions
Considering the key role of CD11a in mediating leukocyte
firm adhesion, we next assessed the effect of the identified
CD11a-upregulating hits on MSC firm adhesion, which is part
of the leukocyte adhesion cascade and is also governed by
CD11a (Luster et al., 2005). CD11a is known to mediate leuko-
cyte firm adhesion with endothelial cells via interaction with
intercellular adhesion molecules, and specifically ICAM-1 (Bha-
tia et al., 2003; Luster et al., 2005). Therefore, we tested firm
adhesion of pretreated MSCs to ICAM-1, which is upregulated
on the endothelial surface at sites of inflammation and is
involved in leukocyte recruitment during inflammation (Kim
et al., 2001; Luster et al., 2005; Wong and Dorovini-Zis, 1992).
MSCs were incubated with each of the positive hits, and then
subjected to a firm adhesion assay under physiologically rele-
vant shear flow using a multiwell plate microfluidic system
(Experimental Procedures) (Levy et al., 2013a). Pretreatment
with Ro-31-8425, which upregulated CD11a expression,
induced a >3-fold increase in MSC firm adhesion to an
ICAM-1-coated substrate compared to control, vehicle-treated
MSCs (Figures 2Ai and 2Aii). As depicted in Figure 2Aiii, Ro-31-
8425 pretreatment induced ICAM-1 firm adhesion of a new
MSC sub-population comprising 68% of the entire population,
out of which 7% are CD11a+ (Figure 1C) and the rest
(61%) express other active ICAM-1-binding domains/adhesion
molecules. Ro-31-8425 also increased MSC firm adhesion to
E-selectin-coated surface, further indicating that Ro-31-8425
induces upregulation/activation of additional adhesion mole-
cules on the MSC surface (Figure S3C). In contrast, the PKC in-
hibitor ruboxistaurin (Joy et al., 2005; Tang et al., 2008), which
Figure 1. A Medium-Throughput Screen Identified Ro-31-8425, a Kinase Inhibitor that Upregulates CD11a Expression on the MSC Surface
(A) Native MSCs lack surface expression of CD11a. Cells (HL-60 or MSCs) were incubated with PE-CY5-CD11a Ab and analyzed by flow cytometry (repre-
sentative data from n = 3 independent experiments).
(B) Global screening data obtained from the medium-throughput screening to identify compounds that upregulate CD11a expression on the MSC surface (9,000
compounds in 112 384-well assay plates were screened; green bars, S/B [signal/background ratio]; blue curve, Z0 values). See also Experimental Procedures.
(C) A dose-dependent increase in the percentage of CD11a+ MSCs in response to Ro-31-8425 pretreatment. MSCs were pretreated with DMSO vehicle control
(0.1%) or Ro-31-8425 (0.1, 1, 3 and 10 mM) for 24 hr and CD11a expression levels were assessed by CyTOF analysis. Error bars represent SD (n = 3; blue dots,
CD11a+ MSCs; black dots, CD11a MSCs). *p < 0.05 versus DMSO-treated control MSCs (Tukey’s HSD test).
(D) CD11a mRNA levels in response to Ro-31-8425 pretreatment as analyzed by RT-PCR. MSCs were pretreated with Ro-31-8425 (3 mM), and CD11a mRNA
levels were analyzed at indicated times post pretreatment. Error bars represent SD (n = 3). *p < 0.05 versus DMSO-treated control MSCs (Tukey’s HSD test).also belongs to the chemical family of bisindoles (Figure S3A)
but did not increase MSC CD11a expression in our screen (Fig-
ure S3B), did not improve MSC firm adhesion to ICAM-1-coated
substrates (Figure 2A).
To explore the possible involvement of CD11a in mediating
pretreated MSC firm adhesion to an ICAM-1-coated surface,
we performed Ab blocking experiments (Experimental Proce-
dures). As shown in Figure 2B, incubating with CD11a-blocking
Ab significantly reduced Ro-31-8425-pretreated MSC firm
adhesion to ICAM-1-coated surface (a reduction from 90%
of adhered cells to 50% following CD11a blocking). These
data suggest that CD11a, which was upregulated in response
to Ro-31-8425 pretreatment, is involved in mediating the in-
creased MSC firm adhesion to ICAM-1. However, CD11a block-
ing did not fully abolish Ro-31-8425-pretreated MSC firm
adhesion to control untreated MSC levels, further suggesting
that other ICAM-1-binding ligands are also involved in medi-
ating the increased firm adhesion of Ro-31-8425-treated
MSCs to ICAM-1.CeRo-31-8425-Preconditioned MSCs Home Efficiently to
Inflamed Sites and Exhibit a Potent Anti-inflammatory
Response
Compounds that significantly increased MSC firm adhesion to
ICAM-1 in vitro were then tested in vivo for their ability to pro-
mote targeting of systemically administered MSCs to a distant
site of inflammation. In our murine model, one ear pinna was in-
jected with lipopolysaccharide (LPS) to induce local inflamma-
tion, while the other received a saline injection (Experimental
Procedures). This model was previously established to evaluate
several MSC bioengineering strategies (Levy et al., 2013b; Sar-
kar et al., 2011) and has recently been modified to maximize
sensitivity (Mortensen et al., 2013). Briefly, compound-treated
and vehicle MSCs (stained with different membrane tracker
dyes and mixed at 1:1 ratio) were systemically infused into
mice, and cell homing to the inflamed and control ears was
imaged 24 hr later using intravital microscopy (Figure 3A; Exper-
imental Procedures). Pretreatment with Ro-31-8425 significantly
improved MSC homing to skin in the inflamed ear upon systemicll Reports 10, 1261–1268, March 3, 2015 ª2015 The Authors 1263
Figure 2. Upregulation of CD11a, in Response to Pretreatment with Ro-31-8425, IncreasesMSCFirmAdhesion to an ICAM-1-Coated Surface
In Vitro
(Ai) MSC firm adhesion to an ICAM-1-coated surface following pretreatment with ruboxistaurin (Rubox) or Ro-31-8425 (3 mM for 24 hr, 103 magnification).
(Aii) Quantification of MSC firm adhesion to an ICAM-1 surface in response to pretreatment with ruboxistaurin and Ro-31-8425. Error bars represent SD (n = 3).
Statistically significant difference versus vehicle-treated control is denoted by *p < 0.05 (Tukey’s HSD test).
(Aiii) A pie chart of the percent distribution of MSC population that express active ICAM-1 binding domains following Ro-31-8425 pretreatment.
(B) Ab blocking experiments demonstrate a significant involvement of CD11a in the increased firm adhesion of Ro-31-8425-treatedMSCs to the ICAM-1 surface.
Error bars represent SD (n = 3). Statistically significant difference versus no Ab control and versus isotype control is denoted by *p < 0.05 (Tukey’s HSD test).administration, with an average of 45.2 ± 8.6 cells/mm2 for
vehicle-MSCs and 78.5 ± 15.9 cells/mm2 for Ro-31-8425-
MSCs (69.3 ± 11.3% increase compared to vehicle-treated
MSCs). These data demonstrate a strong relationship among
surface expression of CD11a, ICAM-1 firm adhesion, and hom-
ing of systemically transplanted MSCs to sites of inflammation.
Furthermore, when CD11a was blocked on Ro-31-8425-pre-
treated MSCs prior to systemic infusion, their enhanced homing
response to the site of inflammation was reversed, dropping
from 70% to less than 10% increased homing versus vehicle-
treated MSCs (Figure 3B). These results further implicate
CD11a and other ICAM-1 binding domains that mediate the
enhanced homing response of systemically infused Ro-31-
8425-pretreated MSCs to sites of inflammation. We then sought
to assess the ability of Ro-31-8425-pretreated MSCs, which ex-
hibited increased homing to the inflamed ear, to alleviate the
severity of LPS-induced local inflammation. To evaluate ear
inflammation, ear thickness and local levels of the pro-inflamma-
tory cytokine tumor necrosis factor alpha (TNF-a) in mice ears
were measured 24 hr post-administration of either vehicle or
Ro-31-8425-pretreated MSCs (Experimental Procedures). As
shown in Figure 3C, while mice treated with vehicle control
MSCs exhibited a small reduction in ear thickness (6.3 ±
5.2 mm reduction compared to no MSC treatment), MSCs pre-
treated with Ro-31-8425 exhibited a greater than 3-fold effect
in reducing ear swelling (20.0 ± 5.3 mm reduction). LPS-induced1264 Cell Reports 10, 1261–1268, March 3, 2015 ª2015 The Authorsinflammation resulted not only in ear swelling but also in a signif-
icant increase in local levels of the pro-inflammatory cytokine
TNF-a in the inflamed ear compared to the saline-treated ear
(4.5- ± 1.3-fold TNF-a increase in the inflamed ear versus control
ear; Figure 3D). Consistent with the cell delivery and ear thick-
ness data, the increased TNF-a levels in the inflamed ear were
significantly reduced (50%) by administration of Ro-31-8425-
treated MSCs, whereas vehicle-treated MSCs did not impact
TNF-a levels (Figure 3D). Taken together, these results show
that systemic infusion of Ro-31-8425-pretreated MSCs, which
display CD11a and other ICAM-1 binding domains, increased
homing to inflamed tissues and also results in improved anti-in-
flammatory therapeutic effect.
DISCUSSION
Our multi-step screening process identified small molecules
that increased expression/activation of ICAM-1-binding li-
gands, such as CD11a, on the MSC surface, enhanced MSC
firm adhesion to an ICAM-1-coated substrate, and also pro-
moted MSC homing to sites of inflammation following systemic
administration, resulting in an improved anti-inflammatory res-
ponse. Our findings are supported by a number of previous ap-
proaches that enhanced MSC therapeutic impact via improved
homing to disease sites (Enoki et al., 2010; Ko et al., 2010).
Recently, we have shown that mRNA-induced expression of
Figure 3. Ro-31-8425-Pretreated MSCs Exhibit Increased Homing to Inflamed Sites and an Improved Anti-Inflammatory Impact following
Systemic Administration
(A) Homing of systemically infused MSCs to LPS-induced inflamed mouse ears was assessed 24 hr following cell infusion. An example 2D projection of a 3D
image stack (scale bar, 50 mm) demonstrates homing to the inflamed ear of Ro-31-8425-pretreated MSCs (green cells) compared to vehicle-treated MSCs (blue
cells). MSCs are found in the vascularized region of the skin (left side of image), with the skin surface exhibiting autofluorescence in multiple channels and a
characteristic tiled pattern (right side of image). Ro-31-8425 pretreatment significantly promoted MSC homing versus the vehicle-treated control cells. Error bars
represent SD (**p < 0.01, Tukey’s HSD test; n = 8 mice).
(B) For Ab blocking experiments, Ro-31-8425 or vehicle-pretreated MSCs were washed and incubated for 30 min with mouse anti-human CD11a (clone TS1/22)
or mouse IgG1 isotype control prior to staining with the Vybrant dyes and retro-orbital infusion as described above. Ab blocking experiments demonstrate
involvement of CD11a and other ICAM-1 binding domains in the increased homing response of systemically infused Ro-31-8425-treated MSCs to the inflamed
ear. CD11a-blocked or Ab isotype control-incubated Ro-31-8425-pretreted MSCs were co-injected systemically with vehicle MSCs (1:1 ratio), and the homing
response to inflamed ear was assessed via intravital microscopy. Error bars represent SD (statistically significant difference versus Ab isotype control is denoted
by *p < 0.05 [Tukey’s HSD test]; n = 5 mice per group).
(C) Ro-31-8425-treatedMSCs displayed a superior effect in reducing swollen ear thickness of the inflamed ear compared to nativeMSCs. Error bars represent SD
(*p < 0.05, **p < 0.01, Tukey’s HSD test; n = 8 mice).
(D) MSCs treated with Ro-31-8425 significantly reduced the TNF-a level in the inflamed ear compared to the control ear. Error bars represent SD (**p < 0.01,
Tukey’s HSD test; n = 6 mice).SLeX/PSGL-1 (rolling ligands) resulted in a transient improve-
ment of only 30% in MSC homing in the same local inflamma-
tion model and yielded a limited anti-inflammatory impact
compared to untreated MSCs (Levy et al., 2013b). In this sys-
tem, targeted SLeX/PSGL-1 MSCs required simultaneous
transfection with interleukin-10 (IL-10) mRNA to achieve a func-
tional anti-inflammatory effect (Levy et al., 2013b). Ro-31-8425
pretreatment induced a 70% increase in MSC delivery to an
inflamed site (via increased firm adhesion), which was reversed
when cells were blocked with a CD11a antibody, implicating
CD11a and other ICAM-1 binding domains in mediating the
increased homing response of MSCs to sites of inflammation.
CD11a antibody blocking also significantly inhibited MSC firm
adhesion to ICAM-1 in vitro, though to a lesser extent (50%
inhibition), indicating that the antibody blocking in vivo mayCehave also blocked MSC interaction with additional ligands on
the inflamed endothelium due to steric interference. Interest-
ingly, the in vitro ICAM-1 firm adhesion data, demonstrating a
new ICAM-1-binding MSC sub-population (68% of the entire
population) in response to Ro-31-8425 (composed of 7%
CD11a+ MSCs and an additional sub-population of 61% ex-
pressing other active ICAM-1-binding domains; Figure 2Aiii)
correlates with the in vivo data of an 70% increase in MSC
homing to inflamed sites in response to Ro-31-8425 (Figure 3A).
It is plausible that via modulation of key signaling pathways,
Ro-31-8425 triggers firm adhesion to ICAM-1 (as well as to
E-selectin) by inducing a slight upregulation (or conformational
activation) of multiple adhesion molecules on the MSC surface,
resulting in a broad and coordinated adhesion response. The
improvement in MSC anti-inflammatory impact commensuratell Reports 10, 1261–1268, March 3, 2015 ª2015 The Authors 1265
with the enhanced homing response demonstrated herein sug-
gests that upregulation of firm adhesion ligands, and specif-
ically utilization of the ICAM-1 axis, is an attractive target to
improve the efficacy of cell-based therapies.
The most promising small molecule identified in our study
was the kinase inhibitor Ro-31-8425, previously demonstrated
as a PKC inhibitor (Muid et al., 1991). Interestingly, PKC activa-
tion was shown to stimulate adhesion-mediated MSC retention
in infarcted myocardium upon local administration by activation
of focal adhesion kinase (Song et al., 2013). In our screen, we
found that ruboxistaurin, a bis-indole that is chemically related
to Ro-31-8425, as well as other PKC inhibitors, did not elicit
CD11a expression on MSCs (Figure S3B) and also did not in-
crease MSC firm adhesion to ICAM-1 (Figure 2A). This implies
that the Ro-31-8425-induced increase in RNA levels and sur-
face expression of CD11a, MSC firm adhesion to ICAM-1,
and systemic targeting of MSCs to an inflamed site were not
PKC dependent and potentially involve other kinases that
may be targeted by Ro-31-8425, such as Rsk2, GSK-3b, and
CDK2 (Brehmer et al., 2004). This finding should stimulate
further research to better understand involvement of signal-
transduction pathways in cell homing to sites of inflamma-
tion. Furthermore, correlating cell-surface adhesion receptor
expression to in vitro and in vivo adhesion, and to a therapeutic
response, should enable further improvements for exogenous
cell therapy, in which targeting cells to diseased or damaged
tissues is highly important. The endothelial receptor expression
on vessels in specific tissues is well characterized, providing
zip codes that can be used to help identify new hits to enable
delivery of cells to specific tissues. Hence, small-molecule
pretreatment can potentially serve as an effective methodology
to target cells to virtually any tissue. Overall, the multi-step
screening process described herein should provide an oppor-
tunity to significantly enhance the clinical efficacy of cell-based
therapy.
EXPERIMENTAL PROCEDURES
Cell Culture and Compound Pretreatment
MSCs were purchased from Lonza (donors used were 7F3915, 318006, and
351482) and expanded in mesenchymal stem cell growth medium (MSCGM)
(Lonza). Cells were kept at 37Cwith 5%CO2, and media were changed every
3 days. Cells were passaged using 1% trypsin-EDTA solution. MSCs at pas-
sage 3–7 were used for all experiments. HL-60 cells were purchased from
ATCC and seeded in Iscove’s modified Dulbecco’s medium/GlutaMax con-
taining 20% fetal bovine serum (Life Technologies).
Medium-Throughput Screen
MSCs were seeded on 384-well plates at 3,000 cells per well in MSCGM
medium. Following an overnight incubation, cells were pretreated with a
low (0.1 mM) and high (3 mM) concentration of the compounds for 24 hr
(a total of 9,000 compounds were tested in 112 assay plates). Cells
were washed and then incubated for 1 hr with PE-CY5-conjugated anti-
CD11a monoclonal Ab (clone HI111, BD Biosciences). Expression of
CD11a at the cell surface was detected using the Acumen Explorer, a
laser-scanning fluorescence microplate cytometer. Positive compounds
were counter-screened for their auto-fluorescence by measuring the signal
in the absence of Ab. Shown in Figure 1B is the global screening data.
For further details, including signal/background ratio (green columns)
and the Z0-factor (blue curve) calculations, see Supplemental Experimental
Procedures.1266 Cell Reports 10, 1261–1268, March 3, 2015 ª2015 The AuthorsCell Viability Assay
Pre-confluent MSCs were incubated with Ro-31-8425 at the indicated con-
centrations for 24 hr or 72 hr, and cell viability was assessed via an XTT assay
according to manufacturer’s instructions (ATCC).
Secretomic Analysis of Pretreated MSCs
MSCs (7F3915 or 318006) were seeded at 25,000 cells/well in a 12-well plate.
24 hr later, cells were treated with Ro-31-8425 (3 mM) or 0.1%DMSO (control).
Following 24 hr of treatment, secretomic samples were collected, centrifuged,
and frozen. MSC secretomes were assayed for the presence of cytokines,
chemokines, and growth factors using Bio-plex human 21-plex and 27-plex
immunoassay kits (Bio-Rad), according to the manufacturer’s instructions.
The 27-plex and 21-plex panels consisted of the following analytes: IL-1a,
IL-1b, IL-1Ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40,
IL-12p70, IL-13, IL-15, IL-17, IL-18, CTACK, GROa, HGF, IFN-a2, LIF, MCP-
1, MCP-3, MIF, MIG, b-NGF, SCF, SCGF-b, SDF-1a, TNF-a, TNF-b, TRAIL,
Eotaxin, FGF-2, G-CSF, GM-CSF, IFN-g, IP-10, MIP-1a, PDGF-bb, RANTES,
and VEGF. A standard range of 0.2–3,200 pg/ml was used. Samples and con-
trols were run in triplicate, and standards and blanks in duplicate (three inde-
pendent experiments were performed for each donor).
mRNA Analysis of CD11a and CD18
mRNA levels of CD11a in response to Ro-31-8425 pretreatment of MSCs were
analyzed by qPCR. Specifically, MSCs were treated with Ro-31-8425 (3 mM) or
vehicle control (0.1% DMSO) for 2 hr, 4 hr, 8 hr, 14 hr, or 24 hr. Cells were then
trypsinized, washed with ice-cold PBS, and pelleted (5003 g for 5 min at 4C)
at during the treatment and immediately stored at80C. RNA extraction was
then performed as previously described (Tong et al., 2013), followed by a
qPCR reaction using the following primers: for CD11a: 50-CAGGCTAT
TTGGGTTACACCG-30 (sense); 50-CCATGTGCTGGTATCGAGGG-30 (anti-
sense); for CD18: 50-TGCGTCCTCTCTCAGGAGTG-30 (sense); 50-GGTCCAT
GATGTCGTCAGCC-30 (anti-sense). See also Supplemental Experimental
Procedures.
CyTOF Analysis for Assessing CD11a Expression Levels
To further confirm the screening results, the surface expression of CD11a was
also examined by time-of-flight mass cytometry (CyTOF2, DVS Sciences)
(Newell et al., 2013). This approach, which uses metal-conjugated antibodies
for detection of target proteins, was used to accurately assess CD11a expres-
sion levels on MSCs (using anti-human Nd142-labeled CD11a antibody, clone
HI111) in response to Ro-31-8425, while minimizing any potential interference
by the auto-fluorescent properties of this compound. MSCs were treated with
Ro-31-8425 as indicated and sample preparation was performed per manu-
facturer’s instructions. CyTOF data were analyzed with Cytobank online
data analysis platform (https://www.cytobank.org/). See also Supplemental
Experimental Procedures.
ICAM-1 and E-selectin Firm Adhesion Assay
Cell adhesion experiments were performed using Bioflux1000 (FluxionBio), al-
lowing accurate control over shear flow (Levy et al., 2013a). A special 48-well
plate was used, in which a microfluidic channel (350 ± 70 mm) connects each
pair of adjacent wells (termed inlet and outlet wells). The plate was placed un-
der vacuum and the channels were coated from the inlet with recombinant hu-
man ICAM-1 (5 mg/ml) or E-selectin (5 mg/ml) Fc chimeras and incubated at
37C for 1 hr. Prior to introducing the cells into the channel, a wash with
PBS / from the outlet well was performed for 5 min. Compound-pretreated
MSCs were introduced into the channel, followed by an attachment period of
2 min (no flow applied during the attachment period). Attached cells were then
subjected to increasing shear flow, ranging from 0.25 dynes/cm2 for up to 10
dynes/cm2. Images were acquired using the Montage software and cell adhe-
sion to the ICAM-1-coated channels following subjection to shear flow was
examined.
Ab Blocking Experiments
MSCs pretreated as indicated were detached, washed, and incubated for
30 min with a mouse anti-human CD11a-blocking Ab (clone: TS1/22) or a
mouse IgG1 isotype control. Cells were then introduced into the microfluidic
channel and subjected to a firm adhesion assay on ICAM-1-coated
channels.
Cell Staining for In Vivo Tracking
To track MSCs in vivo, cells were stained with lipophilic membrane dyes with
emission wavelengths in the red (DiI) or far red (DiD) (Invitrogen), with the
dye pair selected based on previous work (Mortensen et al., 2013). MSCs
(106 cells/ml) were incubated with 10 mM DiI or 10 mM DiD in PBS + 0.1%
BSA for 20 min at 37C. MSCs were then washed twice in PBS and mixed in
equal numbers for injection.
In Vivo MSC Homing
C57BL/6 mice (Charles River Laboratories) were anesthetized with keta-
mine/xylazine and their ears shaved 24 hr prior to cell infusion. To induce
an inflammatory response, 30 mg of E. coli lipopolysaccharide in 50 ml saline
was injected into the pinna of the left ear, with 50 ml 0.9% saline injected
into the right ear as a control. To evaluate the impact of Ro-31-8425 pre-
treatment on MSC homing to the inflamed ear, MSCs were incubated in
cell culture media with 3 mM Ro-31-8425 (dissolved in 0.1% DMSO) or
0.1% DMSO vehicle alone as a control for 24 hr before staining and in vivo
administration. Cells were stained prior to infusion as described above. For
Ab blocking experiments, pretreated or control MSCs were washed and
incubated for 30 min with mouse anti-human CD11a (clone TS1/22) or
mouse IgG1 isotype control, followed by two washing steps in PBS prior
to staining with the Vybrant dyes. After staining, 4 3 104 cells of each con-
dition were suspended in 150 ml PBS (pH 7.4) and injected by retro-orbital
vein infusion into each mouse, so that each mouse received vehicle
treated-MSCs of one color and Ro-31-8425 pretreated-MSCs of another.
The stain color pair was switched between mice to correct for detection
sensitivity. To highlight the vasculature, FITC-dextran (2 3 106 kDa) was in-
jected retro-orbitally prior to imaging. Studies were in accordance with U.S.
NIH guidelines for care and use of animals under approval of the institu-
tional animal care and use committees of Massachusetts General Hospital
and Harvard Medical School.
Confocal Fluorescence Microscopy
In vivo homing of MSCs to the skin was imaged (24 hr post-cell infusion) non-
invasively in real time using a custom-built video-rate laser-scanning confocal
microscope designed specifically for live-animal imaging as previously
described (Mortensen et al., 2013). See also Supplemental Experimental
Procedures.
Ear Thickness and TNF-a ELISA
To determine the impact of small-molecule pretreatment on MSC therapeutic
potential, ear swelling was measured. As a baseline, we measured ear thick-
ness of all mice to be used using a caliper (Mitutoyo) and found no difference.
Each measurement was taken three times with the average value recorded,
and care was taken to ensure minimal compression. Inflammation was then
induced as described above. 24 hr later, mice (n = 4–8 per group) were infused
with no MSCs, MSCs (106/20 g body weight) pretreated for 24 hr with 0.1%
DMSO, or MSCs (106/20 g body weight) pretreated for 24 hr with 3 mM Ro-
31-8425. 24 hr after cell infusion, ear thickness was measured using a caliper
as before. To evaluate TNF-a secretion, LPS-induced inflammation and MSC
administration were performed as described above with n = 4–6 mice for each
condition. Mice were sacrificed 24 hr after cell administration, and both ears
were harvested. Ears were then ground in ice-cold extraction buffer (RIPA
with 0.5% Tween-20) using a homogenizer, homogenates were centrifuged
at 13,000 3 g for 10 min at 4C, and the level of mouse TNF-a level in the su-
pernatant samples was quantified using an anti-mouse TNF-a ELISA kit
(BioLegend).
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